Active Pharmaceutical Ingredients Market Research Report - Global Forecast till 2027

Global Active Pharmaceutical Ingredients Market Research Report: Information By Manufacturing Process (Captive Manufacturing and Contract Manufacturing), Type of Synthesis (Synthetic and Biotech), By API Formulation (Generic API and Branded/Innovative API), Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology and others), Molecules (Large Molecule and Small Molecule) and Region - Forecast till 2027

ID: MRFR/Pharma/0876-CR | August 2019 | Region: Global | 157 pages

Please note that the assessment period of report has been updated from 2015-2023 to 2020-2027. Cordially fill the sample form for updated data.

Impact of Covid-19 Outbreak on Active Pharmaceutical Ingredients (API) Market


COVID-19 has impacted every single industry, adversely impacting the global economy. One such industry that has faced the wrath of COVID-19 is the pharmaceuticals. The COVID-19 has disrupted both the production and the supply chain of the pharmaceuticals industry.


China is a significant source for many Active Pharmaceutical Ingredients. China being the epicenter of the outbreak, manufacturing and export were stopped completely as factories were closed to curb the spread of the virus. Additionally, with the virus spreading to the other 150 countries, the production and export-import of active pharmaceutical ingredients APIs from other major countries, like the US and India, are also affected. For instance, according to the FDA, China has 15% of the world’s facilities that manufacture APIs for 370 essential drugs, while the US has 21% of those facilities.


The majority of APIs for generic drug manufacturing across the globe are sourced from India, which also supplies approximately 30% of the generic APIs used in the US. However, the Indian manufacturers rely heavily on APIs from China for the production of their medicine formulations, procuring around 70% from China, the top global producer and exporter of APIs by volume.


In the Hubei province, where COVID-19 occurred, there are 44 companies, such as Puracap Pharmaceutical LLC, and Fresenius Kabi, AG that are FDA-approved and manufacture APIs or supply chemical ingredients to API manufacturers. However, since the lockdown, these companies have been shut down hindering the manufacturing and import-export of API in and around China.


It is not just the US and China that are facing difficulties; the entire global demand and supply are affected.


China, for example, is an important destination for exports from several Latin American economies, and it is the top trading partner of Chile, Peru, and Brazil. Usually, pharma players maintain a buffer stock of ingredients for 2-3 months. However, as the pandemic disruption is expected to last longer, the companies dependent on Chinese APIs will be devasted, and production will be curtailed.


Supply chain disruptions and product exportation restrictions from India resulted from manpower shortages in China’s manufacturing plants. This was caused by the quarantine policies adapted and adopted by different provincial governments in China in response to the virus. Supplies were further impacted by the disruption of logistic and transportation systems, restricting access and movement of products to and from ports.


These disruptions in demand and supply eventually will affect the production, which will affect the growth of the global API market.


There are various schemes and policies undertaken by governments to reduce dependency on China for API.


Steps that the Indian government are planning to promote domestic API manufacturing to reduce dependence on China
China


Additionally, the US has introduced several policies such as exemption of generic drug manufacturers from corporate taxes in Puerto Rico as Puerto Rico was a dominant player in the manufacture of prescription drugs.


It will take some time before manufacturers in China can resume working at their full operational capacity. Till then, countries that are dependent on China need to evaluate and plan for sourcing alternatives.

The Global Active Pharmaceutical Ingredients (API) Market is expected to reach an estimated valuation of USD 215.12 Bn by the end of 2023, recording steady CAGR of over 4% during the forecast period (2018-2023). This projection signals toward a steady upward growth of the market, which is primarily attributable to the global increase in chronic and acute diseases.


Rapid urbanization has caused a change in lifestyles and led to the increase in incidences of chronic diseases such as cancer, diabetes and various pulmonary diseases among others; this is driving the sales of APIs as there is an increased demand for a variety of effective treatment options. Moreover, generic drugs have grown significantly in popularity over the years as patent expirations, particularly on well-known and effective drugs have allowed a superior degree of competition in the market. There are approximately 300 contract manufacturers that make generic API products across 40 different countries worldwide at present.


Although the factors mentioned above are facilitating consistent growth for the market, several challenges are expected to hamper market growth including stringent drug price control policies across various countries. Several countries are implementing regulations which do not allow pharmaceutical companies to set prices freely. Price control is being done in an effort to protect the interest of the global patient population. Notably, increasing scope for high-potency API is projected to provide the market with room to expand during the assessment period. Pharmaceutical companies are quickly shifting their focus towards high potency APIs such as monoclonal antibodies and recombinant proteins. Moreover, ongoing research and development of effective APIs in the industry is expected to prompt further market growth.


The global API market has been segmented on the basis of manufacturing process, type of synthesis, API formulation, application, molecule and region. By manufacturing, the market has been segmented into captive manufacturing and contract manufacturing. The contract manufacturing segment is expected to witness the highest CAGR during the forecast period, this is primarily due to the growing trend of pharmaceutical companies outsourcing API manufacturing, which allows a better focus on core competencies.


By type of synthesis, the market has been segmented into synthetic and biotech, with the former commanding a significant share of the market. However, it is the biotech segment which has been growing considerably over the last few years and is expected to exhibit a relatively higher CAGR due to the reduced side effects associated with biotech synthesis. The biotech segment is further sub-segmented into monoclonal antibodies, recombinant proteins, vaccines and others. Presently, monoclonal antibodies segment holds pole position, while the recombinant proteins segment is projected to grow at the fastest pace during the assessment as recombinant proteins are finding wide range of applications in the pharmaceutical sector.


By API formulation, the market has been segmented into generic API and innovative API. Patent expirations have propelled the generic API segment into leading position with a projected CAGR of 4.62% during the forecast period.


By application, the market has been segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal, urology, and others. Of these, the oncology segment currently accounts for the largest market share. This is owing to the increased occurrences of cancer worldwide. This segment is set to grow at a CAGR of 5.48% during the review period.


By molecule, the market has been segmented into small molecule and large molecule. Although the small molecule segment accounted for the largest market share in 2017, the large molecule segment is set to surpass in the near future and record a higher CAGR during the assessment period. This is primarily due to the growing focus on research and development of innovative APIs such as biologics to cater to the unmet patient needs.


Regional Analysis


Led by North America, the Americas command the largest market share due to a strong presence of competitors in the region. Countries such as U.S. and Canada have high occurrences of chronic and neurological diseases, which is a strong driver of market growth. Europe, is the second largest market for API. The growth of the market in the region can primarily be attributed to the initiatives taken in the region to support the growth of generic drugs. Improvement of pricing and reimbursement policies combined with a large number of manufacturing activities in Europe is creating growth opportunities for the market.


The API market is reaching maturity in developed nations across the globe, which has shifted market focus to the Asia-Pacific region, making it the fastest growing segment during the assessment period. The presence of a truly massive patient population in countries such as India and China, coupled with increasing incidences of chronic diseases in this region is expected to drive market growth. Cheap labor and lower required investments in infrastructure have prompted many reputable pharmaceutical companies to outsource manufacturing to this region, thus facilitating further growth.


Competitive Tracking


Top market players included Merck & Co. Inc., Eli Lilly and Company, GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Boehringer Ingelheim, Teva Pharmaceuticals Industries Ltd, and Sanofi.


Other reputable players who have been identified and analyzed in the report include Bristol-Myers Squibb, AbbVie, AstraZeneca plc, Abbott Laboratories and Johnson & Johnson Services Inc. among others. Research activities and innovation of products with improved efficiency is a key strategy employed by many of the leading pharmaceutical companies mentioned above.

1 Report Prologue

2 Market Introduction

2.1 Scope Of Study 20

2.2 Research Objective 20

2.3 List Of Assumptions 20

2.4 Market Structure 21

3 Research Methodology

3.1 Research Process 23

3.2 Primary Research 24

3.3 Secondary Research 25

3.4 Market Size Estimation 26

3.5 Forecast Model 26

4 Market Dynamics

4.1 Introduction 28

4.1.1 Drivers 28

4.1.1.1 Increasing Occurrences Of Chronic Diseases 28

4.1.1.2 Growth In Abbreviated New Drug Applications (ANDA) 29

4.1.1.3 Rising Acceptance And Uptake Of Biopharmaceuticals 29

4.1.1.4 Growing Importance Of Generics 30

4.1.2 Restraints 30

4.1.2.1 Stringent Regulatory Policies 30

4.1.2.2 Adverse Drug Price Control Policies Across Numerous Countries 30

4.1.3 Opportunities 31

4.1.3.1 Emerging Biosimilar Market 31

4.2 Increasing Scope For High-Potency Active Pharmaceutical Ingredients 31

4.3 Macroeconomic Indicators 31

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 33

5.1.1 Bargaining Power Of Suppliers 33

5.1.2 Bargaining Power Of Buyers 34

5.1.3 Threat Of New Entrants 34

5.1.4 Threat Of Substitutes 34

5.1.5 Intensity Of Rivalry 34

5.2 Value Chain Analysis 35

5.2.1 Research & Development 35

5.2.2 Manufacturing 35

5.2.3 Distribution 35

5.2.4 Marketing & Sales 36

5.2.5 Post-Sales Monitoring 36

5.3 Demand & Supply: Gap Analysis 36

5.4 Pricing Analysis 36

6 Active Pharmaceutical Ingredients Market, By Manufacturing Process

6.1 Introduction 38

6.1.1 Captive Manufacturing 40

6.1.2 Contract Manufacturing 40

7 Active Pharmaceutical Ingredients Market, By Type Of Synthesis

7.1 Introduction 42

7.2 Synthetic 43

7.3 Biotech 44

7.3.1 Monoclonal Antibodies 44

7.3.2 Recombinant Proteins 44

7.3.3 Vaccines 45

7.3.4 Others 45

8 Active Pharmaceutical Ingredients Market, By API Formulation

8.1 Introduction 47

8.2 Generic API 48

8.3 Branded/Innovative API 49

9 Active Pharmaceutical Ingredients Market, By Application

9.1 Introduction 51

9.2 Cardiovascular Disease 54

9.3 Oncology 54

9.4 Neurological Disorders 54

9.5 Orthopedic Disorders 55

9.6 Respiratory 55

9.7 Gastrointestinal Disorders 55

9.8 Urology 56

9.9 Others 56

10 Active Pharmaceutical Ingredients Market, By Molecule

10.1 Introduction 58

10.2 Molecule 58

10.3 Large Molecule 59

10.4 Small Molecule 59

11 Global Active Pharmaceutical Ingredients Market, By Region

11.1 Introduction 61

11.2 Americas 62

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.2.1 North America 65

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.2.1.1 US. 67

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.2.1.2 Canada 69

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.2.2 South America 71

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3 Europe 73

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1 Western Europe 76

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.1 Germany 78

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.2 France 80

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.3 UK 82

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.4 Italy 84

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.5 Spain 86

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.1.6 Rest Of Western Europe 88

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.3.2 Eastern Europe 90

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4 Asia-Pacific 92

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.1 Asia-Pacific 93

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.2 Japan 95

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.3 China 97

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.4 India 99

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.5 Australia 101

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.6 SouthKorea 103

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.4.7 Rest Of Asia-Pacific 105

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.5 Middle East & Africa 107

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.5.1 Middle East And Africa 108

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.5.2 Middle East 110

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.5.2.1 Saudi Arabia 111

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule


11.5.3 Africa 114

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

11.5.3.1 North Africa 116

Active Pharmaceutical Ingredients Market, By Manufacturing Process

Active Pharmaceutical Ingredients Market, By Type Of Synthesis

Active Pharmaceutical Ingredients Market, By API Formulation

Active Pharmaceutical Ingredients Market, By Application

Active Pharmaceutical Ingredients Market, By Molecule

12 Competitive Landscape

12.1 Company Market Share Analysis 119

12.1.1 Introduction 119

12.2 Merger And Acquisition 119

12.3 Major Strategies Adopted By Market Players 120

12.4 Competitive Landscape 121

12.4.1 Introduction 121

12.4.2 Strategic Partnership 121

12.5 Key Developments 122

12.6 Potential Molecules 126

13 Company Profiles

Company Profiles 127

13.1 Sanofi 128

13.1.1 Company Overview 128

13.1.2 Financial Overview 128

13.1.3 Products Offering 129

13.1.4 Key Developments 130

13.1.5 SWOT Analysis 131

13.1.6 Key Strategy 131

13.2 Bayer AG 132

13.2.1 Company Overview 132

13.2.2 Financial Overview 132

13.2.3 Products Offering 133

13.2.4 Key Developments 134

13.2.5 SWOT Analysis 135

13.2.6 Key Strategy 135

13.3 Pfizer Inc. 136

13.3.1 Company Overview 136

13.3.2 Financial Overview 136

13.3.3 Products Offering 137

13.3.4 Key Developments 138

13.3.5 SWOT Analysis 139

13.3.6 Key Strategy 139


13.4 F. Hoffmann-La Roche AG 140

13.4.1 Company Overview 140

13.4.2 Financial Overview 140

13.4.3 Products Offering 141

13.4.4 Key Developments 142

13.4.5 SWOT Analysis 142

13.4.6 Key Strategy 142

13.5 Abbott Laboratories 143

13.5.1 Company Overview 143

13.5.2 Financial Overview 143

13.5.3 Products Offering 144

13.5.4 Key Developments 144

13.5.5 SWOT Analysis 145

13.5.6 Key Strategy 145

13.6 Merck & Co., Inc. 146

13.6.1 Company Overview 146

13.6.2 Financial Overview 146

13.6.3 Products Offering 147

13.6.4 Key Developments 148

13.6.5 SWOT Analysis 149

13.6.6 Key Strategy 149

13.7 Boehringer Ingelheim GmbH 150

13.7.1 Company Overview 150

13.7.2 Financial Overview 150

13.7.3 Products Offering 151

13.7.4 Key Developments 152

13.7.5 SWOT Analysis 152

13.7.6 Key Strategy 152

13.8 Glaxosmithkline Plc (GSK) 153

13.8.1 Company Overview 153

13.8.2 Financial Overview 153

13.8.3 Products Offering 154

13.8.4 Key Developments 154

13.8.5 SWOT Analysis 155

13.8.6 Key Strategy 155

13.9 Novartis AG 156

13.9.1 Company Overview 156

13.9.2 Financial Overview 156

13.9.3 Products Offering 157

13.9.4 Key Developments 158

13.9.5 SWOT Analysis 159

13.9.6 Key Strategy 159

13.10 Eli Lilly And Company 160

13.10.1 Company Overview 160

13.10.2 Financial Overview 160

13.10.3 Products Offering 161

13.10.4 Key Developments 161

13.10.5 SWOT Analysis 161

13.10.6 Key Strategy 162

13.11 Teva Pharmaceutical Industries Ltd 163

13.11.1 Company Overview 163

13.11.2 Financial Overview 163

13.11.3 Products Offering 164

13.11.4 Key Developments 164

13.11.5 SWOT Analysis 165

13.11.6 Key Strategy 165

14 Conclusion

14.1 Key Findings 167

14.1.1 CEO’s Viewpoint 167

14.1.2 Unmet Needs 167

14.1.3 Key Companies To Watch 167

14.1.4 Prediction 167

15 Appendix

15.1 Discussion Blue Print 169

15.1.1 References 171

16 List Of Tables

TABLE 1 MARKET SYNOPSIS 17

TABLE 2 LIST OF ASSUMPTIONS 20

TABLE 3 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 39

TABLE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CAPTIVE MANUFACTURING, BY REGION,

2020–2027 (USD MILLION) 40

TABLE 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING, BY REGION

2020–2027 (USD MILLION) 40

TABLE 6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 43

TABLE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SYNTHETIC, 2020–2027 (USD MILLION) 43

TABLE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOLOGICAL, 2020–2027 (USD MILLION) 44

TABLE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION

2020–2027 (USD MILLION) 44

TABLE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT PROTEINS, BY REGION,

2020–2027 (USD MILLION) 44

TABLE 11 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH, BY VACCINES, 2020–2027 (USD MILLION) 45

TABLE 12 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHERS, BY VACCINES, 2020–2027 (USD MILLION) 45

TABLE 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 48

TABLE 14 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC API, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BRANDED/ INNOVATIVE API, BY REGION,

2020–2027 (USD MILLION) 49

TABLE 16 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

TABLE 17 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION,

2020–2027 (USD MILLION) 54

TABLE 18 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 54

TABLE 19 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,

2020–2027 (USD MILLION) 54

TABLE 20 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 55

TABLE 21 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY, BY REGION, 2020–2027 (USD MILLION) 55

TABLE 22 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION,

2020–2027 (USD MILLION) 55

TABLE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR UROLOGY, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 24 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER APPLICATION, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 25 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 58

TABLE 26 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR LARGE MOLECULE, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 27 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SMALL MOLECULE, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 28 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 29 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 62

TABLE 30 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 63

TABLE 31 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 63

TABLE 32 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 63

TABLE 33 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 63

TABLE 34 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 64

TABLE 35 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 64

TABLE 36 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 65

TABLE 37 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 65

TABLE 38 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 65

TABLE 39 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 66

TABLE 40 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 66

TABLE 41 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66

TABLE 42 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 67

TABLE 43 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 67

TABLE 44 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 67

TABLE 45 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 67

TABLE 46 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 68

TABLE 47 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68

TABLE 48 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 68

TABLE 49 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 69

TABLE 50 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 69

TABLE 51 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 69

TABLE 52 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 69

TABLE 53 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 70

TABLE 54 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 70

TABLE 55 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 71

TABLE 56 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 71

TABLE 57 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 71

TABLE 58 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 72

TABLE 59 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 72

TABLE 60 SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 72

TABLE 61 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73

TABLE 62 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 74

TABLE 63 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 74

TABLE 64 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 75

TABLE 65 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 75

TABLE 66 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 75

TABLE 67 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 76

TABLE 68 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 76

TABLE 69 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 76

TABLE 70 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 77

TABLE 71 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 77

TABLE 72 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 77

TABLE 73 WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 78

TABLE 74 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 78

TABLE 75 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 78

TABLE 76 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 78

TABLE 77 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 79

TABLE 78 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 79

TABLE 79 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 79

TABLE 80 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 80

TABLE 81 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 80

TABLE 82 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 80

TABLE 83 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 81

TABLE 84 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81

TABLE 85 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 81

TABLE 86 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 82

TABLE 87 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 82

TABLE 88 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 82

TABLE 89 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 82

TABLE 90 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83

TABLE 91 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 83

TABLE 92 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 84

TABLE 93 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 84

TABLE 94 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 84

TABLE 95 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 84

TABLE 96 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85

TABLE 97 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 85

TABLE 98 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 86

TABLE 99 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 86

TABLE 100 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 86

TABLE 101 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 86

TABLE 102 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 87

TABLE 103 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 87

TABLE 104 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 88

TABLE 105 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS,

2020–2027 (USD MILLION) 88

TABLE 106 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 88

TABLE 107 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION,

2020–2027 (USD MILLION) 89

TABLE 108 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89

TABLE 109 REST OF WESTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 89

TABLE 110 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 90

TABLE 111 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 90

TABLE 112 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 90

TABLE 113 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 91

TABLE 114 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91

TABLE 115 EASTERN EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 91

TABLE 116 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92

TABLE 117 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 93

TABLE 118 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 93

TABLE 119 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 94

TABLE 120 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 94

TABLE 121 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 94

TABLE 122 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 95

TABLE 123 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 95

TABLE 124 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 95

TABLE 125 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 95

TABLE 126 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 96

TABLE 127 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96

TABLE 128 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 96

TABLE 129 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 97

TABLE 130 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 97

TABLE 131 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 97

TABLE 132 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 98

TABLE 133 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98

TABLE 134 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 98

TABLE 135 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 99

TABLE 136 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 99

TABLE 137 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 99

TABLE 138 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 99

TABLE 139 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100

TABLE 140 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 100

TABLE 141 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 101

TABLE 142 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 101

TABLE 143 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 101

TABLE 144 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 101

TABLE 145 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102

TABLE 146 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 102

TABLE 147 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 103

TABLE 148 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 103

TABLE 149 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 103

TABLE 150 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 104

TABLE 151 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 104

TABLE 152 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 104

TABLE 153 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 105

TABLE 154 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 105

TABLE 155 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 105

TABLE 156 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 106

TABLE 157 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 106

TABLE 158 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 106

TABLE 159 MIDDLE EAST & NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY CONSUMPTION,

2020–2027 (USD MILLION) 107

TABLE 160 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107

TABLE 161 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 108

TABLE 162 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS,

2020–2027 (USD MILLION) 108

TABLE 163 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 108

TABLE 164 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION,

2020–2027 (USD MILLION) 109

TABLE 165 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109

TABLE 166 MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 109

TABLE 167 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 110

TABLE 168 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 110

TABLE 169 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 110

TABLE 170 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 110

TABLE 171 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 111

TABLE 172 MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 111

TABLE 173 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY CONSUMPTION, 2020–2027 (USD MILLION) 111

TABLE 174 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS IMPORT/EXPORT, 2020–2027 (USD MILLION) 111

TABLE 175 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CONSUMPTION MARKET BY TYPE OF SYNTHESIS,

2020–2027 (USD MILLION) 112

TABLE 176 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CONSUMPTION MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 112

TABLE 177 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CONSUMPTION MARKET, BY API FORMULATION,

2020–2027 (USD MILLION) 112

TABLE 178 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CONSUMPTION MARKET, BY APPLICATION,

2020–2027 (USD MILLION) 113

TABLE 179 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CONSUMPTION MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 113

TABLE 180 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 113

TABLE 181 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020–2027 (USD MILLION) 114

TABLE 182 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 114

TABLE 183 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 114

TABLE 184 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 114

TABLE 185 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115

TABLE 186 AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 115

TABLE 187 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS,

2020–2027 (USD MILLION) 116

TABLE 188 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION) 116

TABLE 189 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY BIOTECH, 2020–2027 (USD MILLION) 116

TABLE 190 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020–2027 (USD MILLION) 116

TABLE 191 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117

TABLE 192 NORTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020–2027 (USD MILLION) 117

TABLE 193 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY DEVELOPMENT 122

TABLE 194 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: POTENTIAL MOLECULES 126

17 List Of Figures

FIGURE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: MARKET STRUCTURE 21

FIGURE 2 RESEARCH PROCESS OF MRFR 23

FIGURE 3 TOP-DOWN AND BOTTOM-UP APPROACH 26

FIGURE 4 DRIVERS & RESTRAINTS: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 28

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET 33

FIGURE 6 SUPPLY CHAIN: ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET 35

FIGURE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020 (% SHARE) 39

FIGURE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MANUFACTURING PROCESS, 2020 & 2027 (USD MILLION) 39

FIGURE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 2020 (% SHARE) 42

FIGURE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020 & 2027 (USD MILLION) 43

FIGURE 11 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION 2020 (% SHARE) 47

FIGURE 12 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY API FORMULATION, 2020 & 2027 (USD MILLION) 48

FIGURE 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION 2020 (% SHARE) 52

FIGURE 14 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY APPLICATION, 2020 TO 2027 (USD MILLION) 53

FIGURE 15 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE 2020 (% SHARE) 58

FIGURE 16 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY MOLECULE, 2020 TO 2027 (USD MILLION) 59

FIGURE 17 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 61

FIGURE 18 AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020 (%) 62

FIGURE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 65

FIGURE 20 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020 (%) 74

FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020 (%) 93

FIGURE 22 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020 (%) 107

FIGURE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, MARKET SHARE ANALYSIS 2020 (%) 120

FIGURE 24 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET COMPETITIVE LANDSCAPE (%) 122

Active Pharmaceutical Ingredients or API, in short, are growing in an increscent manner due to the unmatched effects of active chemicals in the drugs and the portions that work on treating the condition. The bridging of foreign manufacturers and local distributors has led to extensive progress in the market over the past few years. The launch of innovative and improved APIs in the market will boost the market’s progress to a great extent in the forthcoming period. Moreover, the constantly growing demand for biotech API has stimulated the firms to present better and new products to address the unmet requirements of the market.


The active pharmaceutical ingredient (API) market globally is expected to expand with a CAGR of 4.93 percent during the forecast period while earning revenues past the USD 215 billion mark by the year 2023. The outlook for growth in the economy is likely to perceive a sweeping rise in the API industry owing to the growing occurrence of chronic disorders such as diabetes, cardiovascular diseases, obesity and other infectious diseases which will lead to the launch of numerous innovative drugs. The rising cases of chronic diseases are also one of the foremost reasons for hospitalization with a huge number of patients with these conditions who may need re-admission in hospitals owing to an infection that can cause other chronic diseases. The expiration of patents of branded drugs has created a serious impression on drug manufacturers, as the companies can incur tremendous losses after expiration. Hence, the producers favor generic drugs over the branded ones. The generics are also expected to be the most rapidly growing type due to patent expirations of many blockbuster drugs.


However, the rapidly increasing scope for high-potency active pharmaceutical ingredients over the last decade has shifted the focus to the new biologics gold rush of recombinant proteins and monoclonal antibodies. As a result of this, the chemical API market for western contract manufacturers, on the whole, has undergone a sharp decline till 2015. Many custom manufacturing organizations (CMOs) have shifted their emphasis to rescheduling plants or manufacturing of higher-value biologics.


Segmental Analysis


The segmental analysis of the market is based on the segments of the manufacturing process, API formulation, application, type of synthesis, molecule, and region. The market segmentation by type of synthesis consists of biotech and synthetic segments. The synthetic segment in 2017 was worth USD 132,690.7 Mn. The manufacturing process based segmentation of the market comprises of contract manufacturing and captive manufacturing. The captive manufacturing segment presently has the significant market share and is expected to remain extremely lucrative throughout the assessment period. The API formulation segments the market into innovative API and generic API. The generic API segment presently held the leading market share in 2017. The segmentation based on molecule has been segmented into small molecule and large molecule. The small molecule segment is expected to maintain its top position till the end of 2023. The application based segmentation of the market has been segmented into oncology, cardiovascular disease, orthopedic disorders, neurological disorders, respiratory, urology, gastrointestinal disorders and others. The oncology segment is anticipated to develop with an incremental CAGR during the forecast period.


Regional Analysis


The market for APIs has been segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas region presently controls the significant market portion, and the trend will probably carry on in the foreseeable future. This factor is majorly related to the robust value sustained by the small molecule segment in both Canada and the U.S. Additionally the pharmaceutical industry is among one of the major and most exceptional ventures in the US nations. The pharmaceutical organizations in the USA have developed quickly in comparison with other countries. The European and Asia Pacific region are also anticipated to continue growth in the revenue pockets for the active pharmaceutical ingredients (API) market during the forecast period. Europe accounts for the second largest market for active pharmaceutical ingredients which is followed by the Asia Pacific region. While the APAC region, the market’s course is mostly directed by factors such as the amplified level of expense on equipment and infrastructure, expanding initiatives which are motivating investment in APIs from drug makers to increase the capacity to produce APIs.


Competitive Analysis


The players and key trends have created a positive tone for development. The competitors in the market are also leveraging their competitive benefits to secure their development in the market. The market progress by competitors also encompasses strong risk management strategies which are positively motivating the expansion of the market.


Bayer AG, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi, Boehringer Ingelheim GmbH, Abbott Laboratories, GlaxoSmithKline Plc (GSK), Novartis AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.